• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Treace Medical Concepts Inc.

    4/2/24 4:30:07 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email
    DEFA14A 1 2024_tmci_defa_14a_for_f.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

    Treace Medical Concepts, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


    img52561901_0.jpg 

     


     

    2022 11:59 PM ET TREACE MEDICAL CONCEPTS, NC. 203 FT WADE RD SUITE 150 PONTE VEDRA, FL 32081 D74141-P70376 You invested in TREACE MEDICAL CONCEPTS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 17, 2022. Get informed before you vote View the Notice and Proxy Statement, Annual Report and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 3, 2022. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 17, 2022 11:00 a.m., Eastern Time Virtually at: www.virtualshareholdermeeting.com/TMCI2022 *Please check the meeting materials for any special requirements for meeting attendance. V1.1OT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 01) Lawrence W. Hamilton 02) Deepti Jain 03) James T. Treace For For 2. Proposal to ratify the appointment of Grant Thornton LLP as independent auditor for the year ending December 31, 2022. NOTE: In their discretion, upon such other matters that may properly come before the meeting or any adjournment or adjournments thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. D74142-P70376img52561901_1.jpg


    Get the next $TMCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    11/7/2025$5.00Neutral → Underweight
    Analyst
    11/7/2025Buy → Neutral
    BTIG Research
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    More analyst ratings

    $TMCI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    2/12/26 5:57:53 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    1/13/26 8:54:59 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    12/18/25 8:44:09 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology

    PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace's market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, precisely correct in all three planes, and further streamline procedural workflow with Treace's SpeedPlate® Rapid Compression Fixation technology. "As the pioneers and leaders in instrumen

    1/8/26 4:05:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Treace Medical Concepts downgraded by Analyst with a new price target

    Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:29:21 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts downgraded by BTIG Research

    BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

    11/7/25 8:29:10 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts upgraded by BTIG Research with a new price target

    BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

    2/4/25 7:10:07 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Scanlan Sean F. exercised 16,875 shares at a strike of $1.05, increasing direct ownership by 2% to 706,474 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    2/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Scanlan Sean F. exercised 53,500 shares at a strike of $0.72 and was granted 262,500 shares, increasing direct ownership by 85% to 689,599 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:05 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. covered exercise/tax liability with 14,254 shares and was granted 250,000 shares, increasing direct ownership by 3% to 7,011,633 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/4/25 6:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    9/17/24 5:17:19 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    8/19/24 9:00:08 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Financials

    Live finance-specific insights

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Reports Third Quarter 2025 Financial Results

    PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $50.2 million in third quarter 2025 representing growth of 11% over the same period in 2024. Reported third quarter 2025 net loss of $(16.3) million and improved adjusted EBITDA by 49% to $(2.6) million in the third quarter 2025 compared to $(5.1) million in the same period in 2024.Presented clinical data at the American

    11/6/25 4:05:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

    SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/12/24 6:01:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/8/24 3:44:13 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    View All

    Treace Appoints Guy Guglielmino as Chief Commercial Officer

    PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

    12/2/24 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

    PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

    8/21/23 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

    PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

    7/12/23 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care